2-4 May 2007 sees the 17th conference of the European Wound Management Association at Glasgow's Scottish Exhibition and Congress Centre.
Exhibiting for the first time, young Bedford based biotechnology firm, Archimed, will be previewing its latest product, Oxyzyme(tm), which is part of an innovative new range of oxygen-concentrating hydrogel wound dressings.
Oxyzyme(tm) uses advanced biochemistry to create a moist barrier that actively transports dissolved oxygen into the wound, but which remains impassable to bacteria. The overall effect is to enable epithelialisation and prevent premature scabbing.
Company founder Prof. Paul Davis, a leader in the field of applied immunology and biotechnology (one of the scientists involved with producing the first home pregnancy tests - Clearblue®), is particularly excited at the potential of this latest product innovation. "Early indications have shown Oxyzyme(tm) to be particularly effective in tackling hard-to-heal wounds*," comments Davis. "We believe that it will provide significant and tangible improvements in wound care."
Prof. Davis will be available for interview during the conference and, along with leading authorities in wound care, Profs. Gary Sibbald and David Leaper, he will be speaking on "The Role of Oxygen in Wound Healing" on Wednesday 2nd May 2007, 16:00-17:00 in EWMA seminar room 'Dochart 1'.
For more information please contact: email@example.com